1. Home
  2. BFRG vs PCSA Comparison

BFRG vs PCSA Comparison

Compare BFRG & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bullfrog AI Holdings Inc.

BFRG

Bullfrog AI Holdings Inc.

N/A

Current Price

$1.00

Market Cap

13.1M

Sector

Technology

ML Signal

N/A

Logo Processa Pharmaceuticals Inc.

PCSA

Processa Pharmaceuticals Inc.

N/A

Current Price

$6.67

Market Cap

8.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BFRG
PCSA
Founded
2017
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.1M
8.0M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
BFRG
PCSA
Price
$1.00
$6.67
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$1.00
AVG Volume (30 Days)
65.3K
2.0M
Earning Date
11-14-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$116,670.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.80
$0.11
52 Week High
$4.84
$3.35

Technical Indicators

Market Signals
Indicator
BFRG
PCSA
Relative Strength Index (RSI) 41.06 96.88
Support Level $1.10 $0.11
Resistance Level $1.21 $0.30
Average True Range (ATR) 0.07 0.43
MACD 0.01 0.40
Stochastic Oscillator 13.97 74.80

Price Performance

Historical Comparison
BFRG
PCSA

About BFRG Bullfrog AI Holdings Inc.

Bullfrog AI Holdings Inc is a clinical-phase Biotechnology company using machine learning to advance medicine and improve human health. It uses artificial intelligence and machine learning to advance medicines for both internal and external projects. Its platform technology, named, bfLEAP, is an analytical AI/ML platform that is able to surmount the challenges of scalability and flexibility currently hindering researchers and clinicians by providing a more precise1, multi-dimensional understanding of its data.

About PCSA Processa Pharmaceuticals Inc.

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).

Share on Social Networks: